Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023
SKU ID : TNV-14098771 | Publishing Date : 29-Mar-2019 | No. of pages : 121
Detailed TOC of Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY ROA
• Market segmentation by RoA
• Comparison by RoA
• Oral - Market size and forecast 2018-2023
• Parenteral - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by RoA
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Bausch Health
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• Merck & Co., Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global CMV therapeutics market pipeline: Overview
Exhibit 18: Global CMV therapeutics market pipeline: Overview
Exhibit 19: RoA - Market share 2018-2023 (%)
Exhibit 20: Comparison by RoA
Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 23: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by RoA
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AstraZeneca - Vendor overview
Exhibit 52: AstraZeneca - Product segments
Exhibit 53: AstraZeneca - Organizational developments
Exhibit 54: AstraZeneca - Geographic focus
Exhibit 55: AstraZeneca - Key offerings
Exhibit 56: AstraZeneca - Key customers
Exhibit 57: Bausch Health - Vendor overview
Exhibit 58: Bausch Health - Business segments
Exhibit 59: Bausch Health - Organizational developments
Exhibit 60: Bausch Health - Geographic focus
Exhibit 61: Bausch Health - Segment focus
Exhibit 62: Bausch Health - Key offerings
Exhibit 63: Bausch Health - Key customers
Exhibit 64: F. Hoffmann-La Roche Ltd - Vendor overview
Exhibit 65: F. Hoffmann-La Roche Ltd - Business segments
Exhibit 66: F. Hoffmann-La Roche Ltd - Organizational developments
Exhibit 67: F. Hoffmann-La Roche Ltd - Geographic focus
Exhibit 68: F. Hoffmann-La Roche Ltd - Segment focus
Exhibit 69: F. Hoffmann-La Roche Ltd - Key offerings
Exhibit 70: F. Hoffmann-La Roche Ltd - Key customers
Exhibit 71: Gilead Sciences, Inc. - Vendor overview
Exhibit 72: Gilead Sciences, Inc. - Business segments
Exhibit 73: Gilead Sciences, Inc. - Organizational developments
Exhibit 74: Gilead Sciences, Inc. - Geographic focus
Exhibit 75: Gilead Sciences, Inc. - Key offerings
Exhibit 76: Gilead Sciences, Inc. - Key customers
Exhibit 77: Merck & Co., Inc. - Vendor overview
Exhibit 78: Merck & Co., Inc. - Business segments
Exhibit 79: Merck & Co., Inc. - Organizational developments
Exhibit 80: Merck & Co., Inc. - Geographic focus
Exhibit 81: Merck & Co., Inc. - Segment focus
Exhibit 82: Merck & Co., Inc. - Key offerings
Exhibit 83: Merck & Co., Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Keyplayers in Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023
AstraZenecaBausch Health
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
Merck & Co., Inc.